Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
I thought the patients has cancer types that did not respond to Dox, or was it patients had not been treated with it?
Does this mean that the market for AVA6000 is bigger than thought?
Thanks BV.
Would that mean applying a line through the data and projecting it forward would create an inaccurate impression of outcomes?
Not a mathematician
And apologies all for my typos, small keyboard, old eyes, etc etc
@BV thanks, should have thought of that.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116111/#:~:text=There%20are%20two%20proposed%20mechanisms,1)%20%5B9%5D.
1. I think this is saying it buggers DNA so that the cell can make stuff it needs to make
2. It releases nasty s*** when broken down in a cell that really buggers cells
lots of abbreviations and funny latin/greek words.
cancer cells diving, so targets them, but really does a number of lots of other cells as well.
Guess one challenge is to make just right amount of dox from the precision stuff, so it is taken up at target, and not so much that its can't be taken up in cancer environment and leaks out systemically and kill the patient. Alternative, at some point the curve may level off cause FAP is saturated and can only convert so much per hour.
they should test to see where this happens, it could kill someone rather than treat them. Not a doctor.
Pl could you give me a polynomial of bean count to plate angel. Please show your working. Is the area under the curve a measure in calories or carpet stains ?
@jive’ just pulling your chain.
No need to wrap up the feeling of good news with the mumbo jumbo BS his lordship spouts to pump and dump/make himself feel important.
I scanned the pdf quickly, but not sure if numbers seen in tumors have been seen with straight dox ever. anyone know? Can anyone say what that effect will be. 3 times concentration might not mean 3 times the effect. Or does it ? Might be more, might be less. Guess why there is pb1 for different tumor types.
Freely admit I have no idea.
Your second part about pathways is interesting. I’m
hanging on by finger tips, can you put it in layman’s terms how this stuff works when it becomes dox.
Thanks
Monkhood would affirmers help grab those volatile compounds?
Https://amp.theguardian.com/society/2023/jun/04/uk-trials-for-cancer-breath-tests-reach-final-stages
Given the car crash that was the lfd, it’s not even as if Prof Waffle even likes DX.
Are we saying midsummer ?
ta very much.
HAVE YOU HEARD, SMITH BOUGHT A HOUSE
Did this expert have a dog?
Madness takes it toll.
Lordships timeline wasn’t a timeline.
Even the donkey can’t stop laughing.
7 reptiles ?
RD, I think rehearsals for Panto season start in September, ready for end of year pumping, so expect some “oh no he’s not” around then.
Thanks for posting
I guess the big money has flown away, mainly to the east. Covid hasn't gone away, and can still make people pretty poorly (and yes it is still a killer for some).
For someone running a business, the last ting you want as recovery happens if for half your workforce to call in laid up in bed. Protecting productivity will be a priority for many, and the best way to do that is to issue LFD to employees. If you are not feeling well, take the test. If +ve send image to HR and stay at home for a week. If -ve, follow advice, pick up another LFD from the office.
In addition for asymptomatic, test every one on a given day.
the cost of protecting productivity is minor compared to spreading illness through the organisation. Less than the coffee machine costs.
Protecting means using a test which is good quality, why spend money on crap (different if test are paid for by public purse). Maybe some marketing to get this message across would be appropriate early through summer. Even though peak money has gone, a steady flow of cash into the business 6 month a year would give it a good base for operations, and if that happens should raise SP nicely.
anyone thinks differently, I kinda think I am just crossing my fingers to be honest.
hmmm so the share a few years ago was worth on this day 2020 24-28p
1. since then we have had a debacle where company has shown it lacks experience in a goto market plan in the DX space.
On the plus side
1. lots of money in the bank to drive TX
2. phase 1 of a drug started
3. 2nd candidate announced (although there have been news before)
4. others believing in the TX tech and partnering to take it to big markets
so the share has doubled on the +ve in 2 years.
I think any further decline is SP would be odd, just looking at how the market prices risk/reward generally.
The current SP is odd. TO ca 3 -5 billion would not be an unreasonable expectation with similar deals in the past, but time needed to reduce risk for big pharma. Thats a nice risk/reward in my book if you can wait.
so only conclusion is loss of confidence in CEO performance last week, and that mainly around DX.
so fix is easy, switch out CEO for someone with a better take it to market/manufacture profile, or become better at working with DX partners by placement of someone with that experience. Avacta have had affimers on books for a long time and have struggled to DX partner despite many possible applications. I don't know why, if it's something technical it would be interesting to know. I suspect it's a mental inability to allow others make lots of money from your commodity IP (antibody = commodity) combined with no experience in the heavy lift of production/sales.
alternative, suck it up, and wait for TX which is the main carrier if value. I have enough in this share to hurt, but young enough not to panic over timescale. Not buying even at this price, but only cos I spread my investments.